At a glance
- Company
- SS Innovations International
- Ticker
- NASDAQ: SSII
- Announcement
- Executive
Key figures
- Funds raised during Romano’s career
- more than $100 million
- Healthcare professionals in inaugural training class
- 33
- Countries represented in inaugural training class
- seven
People
- Sarah M. RomanoChief Financial Officer
Products and programs
- The company has appointed veteran medtech finance executive Sarah M. Romano as Chief Financial Officer, effective August 3, 2026.
- Romano brings more than two decades of experience in public-company finance, capital markets, and medical technology, having raised more than $100 million during her career.
- The appointment comes as SS Innovations continues pursuing U.S. FDA clearance for its SSi Mantra surgical robotic system while expanding internationally.
- The company recently graduated the inaugural class of its SS International Centre for Robotics Surgery (“SSICRS”) cardiac robotic surgery training program.
- SSICRS welcomed 33 healthcare professionals from seven countries, underscoring the company’s emphasis on surgeon education alongside technology deployment.
SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has appointed veteran medical technology finance executive Sarah M. Romano as chief financial officer, adding public-company financial and capital markets experience as the surgical robotics developer continues its global expansion and advances regulatory initiatives. The appointment, effective August 3, comes at a time when SS Innovations is pursuing broader commercialization of its SSi Mantra robotic surgical platform while continuing preparations for U.S. Food and Drug Administration review (https://nnw.fm/yY4UM).
Romano joins SS Innovations after serving as chief financial officer at Vicarious Surgical, another developer of robotic surgical technologies, where she oversaw financial and operational initiatives designed to reduce cash burn, strengthen the company’s balance sheet and support…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Questions around this news
Who is Sarah M. Romano, and when will she become CFO?
Sarah M. Romano is a medical technology finance executive with more than two decades of experience in public-company finance and capital markets. The release says she has raised more than $100 million during her career and previously served as CFO of Vicarious Surgical. Her appointment as chief financial officer of SS Innovations is effective August 3, 2026.
What is the SSi Mantra system, and what regulatory step is the company pursuing?
The SSi Mantra is SS Innovations’ surgical robotic system. The release says the company is pursuing U.S. Food and Drug Administration clearance for the system as it continues preparations for FDA review and seeks broader commercialization. It does not provide a timeline for a decision or describe the specific clearance pathway.
What is the SSICRS cardiac robotic surgery training program?
The SS International Centre for Robotics Surgery recently graduated the first class of its cardiac robotic surgery training program. According to the release, 33 healthcare professionals from seven countries took part. The company presents surgeon education as part of its approach alongside deploying its surgical technology internationally.
What does FDA clearance generally mean for a medical device?
FDA clearance is an agency decision that allows a medical device to be marketed in the United States through a particular regulatory pathway. The review and evidence required depend on the device and pathway. Clearance is distinct from FDA approval, which applies to other types of regulatory submissions.
